The Eugeroics: Modafinil, Armodafinil, Adrafinil, Flmodafinil

Eugeroics, from the Greek "good arousal", are wakefulness-promoting compounds that increase alertness without acting as classical stimulants. Modafinil is the canonical example; the family includes armodafinil, adrafinil, and various less-common variants. Each has a slightly different pharmacological profile, regulatory status, and use case.

This is a category with real clinical evidence and meaningful effects. It's also one where prescription requirements vary by jurisdiction and grey-market sourcing is common. The legal and practical considerations differ from over-the-counter supplements.

Modafinil

The original eugeroic, developed in France in the 1970s by Michel Jouvet at Laboratoire Lafon. Approved for narcolepsy in France in 1994, US (as Provigil) in 1998.

Mechanism: dopamine reuptake inhibition via the dopamine transporter (DAT). Also activates orexin/hypocretin neurons (the master wakefulness signal), modulates histamine, norepinephrine, and serotonin. The polypharmacology produces wakefulness without the euphoric surge that drives amphetamine abuse.

Effects: 12-15 hour wakefulness windows. Improved executive function and working memory (Battleday & Brem 2015 meta-analysis of 24 studies in non-ADHD adults). Reduced fatigue under sleep deprivation.

Dose: 100-200 mg, single morning dose. Taken before 9 AM to protect sleep.

Side effects: headache (common), anxiety, Stevens-Johnson syndrome (rare but severe), reduced hormonal contraceptive efficacy (clinically significant for women on OCPs).

Schedule IV in US; prescription-only in nearly every jurisdiction. The legal grey market consists primarily of Indian generic versions imported personally.

Armodafinil

The pure R-enantiomer of modafinil. Cephalon developed and commercialised it as Nuvigil; FDA approved 2007.

Mechanism: identical to modafinil, the R-enantiomer is the more active form. The S-enantiomer in racemic modafinil contributes little to the wakefulness effect but has shorter half-life.

Effects: similar to modafinil with slightly longer effective half-life and smoother peak-to-trough curve from a single morning dose.

Dose: 75-150 mg (half the modafinil dose because the R-enantiomer is purified). Single morning dose before 8 AM.

The commercial rationale for armodafinil was patent extension as modafinil approached generic status in 2012. Clinically, the differences from modafinil are subtle. The choice between them is mostly personal preference based on subjective tolerance.

Indian generic versions: Waklert and Artvigil from Sun Pharma and HAB Pharma respectively. Same grey-market dynamics as modafinil.

Adrafinil

A prodrug, hepatic conversion to modafinil is the source of activity. Developed by Laboratoire Lafon in the 1970s before modafinil was synthesised directly.

Mechanism: hepatic conversion to modafinil. Onset is 30-60 minutes delayed vs direct modafinil.

Effects: equivalent to modafinil once conversion is complete.

Dose: 300-1200 mg. The conversion ratio means doses are 3-4x higher than equivalent modafinil dose.

The conversion places hepatic load that direct modafinil doesn't. Long-term adrafinil use has been associated with liver enzyme elevation in case reports. Most users who consider adrafinil should consider direct modafinil instead if sourcing allows.

Unscheduled in US and UK; prescription-only in some jurisdictions. The legal status is the main attraction for users where modafinil is prescription-restricted.

Flmodafinil (Lauflumide, CRL-40,940)

A modafinil analogue with fluorinated structure. Higher potency than modafinil at lower doses; reportedly longer half-life. Limited human data.

Sold as research chemical in some markets. Not approved or regulated as a pharmaceutical.

Dose claims vary; typically 50-100 mg are reported as roughly equivalent to 100-200 mg modafinil. Subjective effect reports describe similar wakefulness with somewhat different texture.

The thin human safety data and regulatory grey status make this category higher-risk than modafinil itself. The advantages over established modafinil are unclear.

Bismodafinil

Another modafinil derivative with even less human data. Reported by some users as having faster onset and smoother profile but the published literature is essentially absent.

Skip unless specifically experimenting. The risk-benefit profile relative to modafinil is unfavorable for most use cases.

Practical comparison

For users with prescription access: modafinil is the first choice. The evidence base is largest, the safety profile is best-characterised, and the dose is well-established.

For users with regular use needs and good response: armodafinil produces smoother subjective effect with slightly longer duration.

For users in jurisdictions where modafinil is prescription-restricted and direct sourcing is problematic: adrafinil is the legal-but-imperfect alternative. The hepatic load concern is real but typically tolerable at intermittent doses.

For users seeking experimental experience: the various analogues exist but with substantially less safety data and clear evidence base.

Use frequency

The strongest argument for eugeroics in cognitive enhancement use is intermittent rather than daily dosing. Daily modafinil produces tolerance over weeks; intermittent (2-3 times per week) maintains response indefinitely.

Single intense work weeks before deadlines work well with daily modafinil for 5 consecutive days, followed by a 2-3 day washout. Pushing past this pattern produces declining response and sleep accumulation problems.

Interactions

Hormonal contraceptive efficacy: modafinil and armodafinil reduce OCP efficacy. Women on OCPs should use additional contraception or alternative birth control during regular eugeroic use.

CYP3A4 substrates: modafinil mildly induces CYP3A4, potentially reducing levels of medications cleared by this pathway. Most clinically relevant for some birth control pills, some immunosuppressants, and some seizure medications.

Caffeine: additive cardiovascular load. Most modafinil users reduce caffeine substantially on modafinil days.

Other stimulants: stacking modafinil with high-dose caffeine, methylphenidate, or amphetamines produces overstimulation. Combinations should be avoided.

SSRI users: generally compatible. Modafinil's dopamine-focused mechanism doesn't significantly overlap with SSRI serotonin reuptake inhibition.

The honest assessment

Modafinil produces real, replicable cognitive benefits for the majority of users who take it. The effects are larger and more reliable than essentially any over-the-counter alternative. The catch is the prescription requirement and the cardiovascular and sleep effects that limit chronic use.

For users with prescription access for narcolepsy, shift work sleep disorder, or sleep apnea, modafinil prescription use is straightforward. For users seeking off-label cognitive enhancement, the grey market access is real but carries legal and quality risks.

The supplement alternatives (caffeine + theanine, tyrosine, the slow-build cognitive stack) produce smaller but more sustainable benefits without the prescription or sourcing complications. Whether modafinil is worth the additional access friction depends on individual circumstance.